FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP
• = =	J. J		• • • • • • • • • • • • • • • • • • • •

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cherrington Julie M				2. Issuer Name and Ticker or Trading Symbol Vaxart, Inc. [VXRT]					(Ch	eck all applic	able) r	10% Owner			
(Last) (First) (Middle) C/O VAXART, INC. 170 HARBOR WAY, SUITE 300				3. Date of Earliest Transaction (Month/Day/Year) 08/20/2021						Officer below)	(give title	Othe belov	(specify		
(Street) SOUTH FRANCI	SAN C		94080	4.	If Amer	ndment, [Oate (of Original File	ed (Month/Da	ay/Year)	Line) <mark>X</mark> Form fi	led by One I	Filing (Check Reporting Per than One Re	son
(City)	(S	tate)	(Zip)												
1. Title of Security (Instr. 3) 2. Transac Date			ransaction	Execution Date, if any (Month/Day/Year) Execution Date, Odd (Instr. 3, 0) (Instr. 3,			ed (A) or	5. Amour Securitie Beneficia	nt of	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial				
							r) 8)	+		Price	Owned F Reported Transact (Instr. 3 a	ollowing (l ion(s)	(I) (Instr. 4)	Ownership (Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	or Exercise (Month/Day/Year) if any		Execution Date,	Code (Transaction Code (Instr. 8) Sc AA (A Di ot			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form: Direct (I or Indire (I) (Instr	Beneficial Ownership ct (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$8.34	08/20/2021		A		65,700		(1)	08/19/2031	Common stock	65,700	\$0	65,700	D	

Explanation of Responses:

1. The shares subject to this option shall vest annually over three years from the vesting commencement date of August 20, 2021, the date of the grantee's appointment as a director of Vaxart, Inc.

/s/ Margaret Echerd, Attorneyin-Fact for Julie Cherrington

08/23/2021

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents that the undersigned hereby constitutes and appoints each of Andrei Floroiu, Margaret Echerd, Faith L. Charles, Esq., and Naveen Pogula, Esq., or any of them signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC")
 a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned
 to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the
 SEC:
- 2. execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Vaxart, Inc. (the "*Company*"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- 3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
- 4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 8th day of August 2021.

/s/ JULIE MICHELE CHERRINGTON, PhD
Name: JULIE MICHELE CHERRINGTON, PhD